Results 21 to 30 of about 23,498 (195)

Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers

Arquivos de Neuro-Psiquiatria, 2015
Objective Analyze the demographics, clinical characteristics, efficacy and safety of natalizumab treatment in Brazilian patients with multiple sclerosis (MS) followed up for at least 12 months, in two tertiary MS care centers in São Paulo.Method We ...
Enedina Maria Lobato de Oliveira, Renata Faria Simm, Gorana Dasic, Marília Mamprim de Morais, Samira Luiza dos Apostolos Perreira, Dagoberto Callegaro   +5 more
doaj   +1 more source

Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis? [PDF]

PLoS ONE, 2017
Progressive multifocal leukoencephalopathy (PML) is one of the major risks of natalizumab therapy. Despite introduction of the currently employed PML risk stratification algorithm, the incidence of natalizumab-associated PML cases is not decreasing.We ...
Julia Krämer, Jan-Gerd Tenberge, Ingo Kleiter, Wolfgang Gaissmaier, Tobias Ruck, Christoph Heesen, Sven G Meuth   +6 more
doaj   +1 more source

Comparative effectiveness of natalizumab ocrelizumab in multiple sclerosis: a real-world propensity score–matched study

Therapeutic Advances in Neurological Disorders, 2022
Background: For treatment of relapsing-remitting multiple sclerosis (RRMS), a broad range of disease-modifying therapies (DMT) is available. However, few comparative effectiveness studies between different drugs have been performed.
Katrin Pape, Leoni Rolfes, Falk Steffen, Muthuraman Muthuraman, Melanie Korsen, Sven G. Meuth, Frauke Zipp, Stefan Bittner   +7 more
doaj   +1 more source

Piloting home infusions of Tysabri (natalizumab): a randomised crossover trial

International Journal of Integrated Care, 2019
We developed a new model of care for home infusions of natalizumab for people with multiple sclerosis. The new model of care was then tested in a pilot study comparing home infusions of natalizumab with usual care (attendance in an ambulatory care day ...
Tim Schultz, Anne Thomas, Paul Georgiou, Mahasen Juaton, Lorraine Simon, Lynette Cusack, Kerisha Naidoo, Kevin Webb, Jon Karnon   +8 more
doaj   +1 more source

Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis. [PDF]

PLoS ONE, 2012
Natalizumab is a recombinant monoclonal antibody raised against integrin alpha-4 (CD49d). It is approved for the treatment of patients with multiple sclerosis (MS), a chronic inflammatory autoimmune disease of the CNS. While having shown high therapeutic
Thomas F Benkert, Lena Dietz, Elena M Hartmann, Ellen Leich, Andreas Rosenwald, Edgar Serfling, Mathias Buttmann, Friederike Berberich-Siebelt   +7 more
doaj   +1 more source

Natalizumab para la esclerosis múltiple remitente-recurrente

Neurología, 2011
Resumen: Introducción: Natalizumab es un anticuerpo monoclonal inhibidor de la migración leucocitaria a través de la barrera hematoencefálica, autorizado para el tratamiento de la esclerosis múltiple remitente-recurrente. Objetivo: Realizar una revisión
A. Horga, M. Tintoré
doaj   +1 more source

A programme for risk assessment and minimisation of progressive multifocal leukoencephalopathy developed for vedolizumab clinical trials [PDF]

, 2018
Introduction Over the past decade, the potential for drug-associated progressive multifocal leukoencephalopathy (PML) has become an increasingly important consideration in certain drug development programmes, particularly those of immunomodulatory ...
Berger, Joseph R, Clifford, David B, Fox, Irving, Lev, Michael H, Major, Eugene, McAuliffe, Megan, Milch, Catherine, Parikh, Asit, Patti, Mark, Provenzale, James M, Sankoh, Serap, Shick, Jesse, Stephens, Kristin   +12 more
core   +3 more sources

Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.

PLoS ONE, 2012
In multiple sclerosis (MS), treatment with the monoclonal antibody natalizumab effectively reduces the formation of acute lesions in the central nervous system (CNS).
Lars Börnsen, Jeppe Romme Christensen, Rikke Ratzer, Annette Bang Oturai, Per Soelberg Sørensen, Helle Bach Søndergaard, Finn Sellebjerg   +6 more
doaj   +1 more source

High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients

Therapeutic Advances in Neurological Disorders, 2021
Aims: To retrospectively assess factors associated with John Cunningham virus (JCV) seroconversion in natalizumab-treated patients. Background: Natalizumab is highly effective for the treatment of relapsing–remitting multiple sclerosis (RRMS), but its ...
Christopher M. Dwyer, Vilija G. Jokubaitis, Jim Stankovich, Josephine Baker, Jodi Haartsen, Helmut Butzkueven, Adriana Cartwright, Neil Shuey, Yara Dadalti Fragoso, Louise Rath, Olga Skibina, Kylie Fryer, Ernest Butler, Jennifer Coleman, Jennifer MacIntrye, Richard Macdonell, Anneke van der Walt   +16 more
doaj   +1 more source

Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions. [PDF]

, 2020
ObjectiveTo determine the transfer of rituximab, an anti-CD20 monoclonal antibody widely used for neurologic conditions, into mature breast milk.MethodsBreast milk samples were collected from 9 women with MS who received rituximab 500 or 1,000 mg ...
Anderson, Annika, Bevan, Carolyn, Bove, Riley, Hale, Thomas W, Krysko, Kristen M, LaHue, Sara C, Marcus, Jacqueline, Riley, Claire S, Rowles, William, Rutatangwa, Alice, Schubert, Ryan D   +10 more
core   +1 more source